Holen Sie sich die Stockscreener-App
3.04
1.33%
0.04
Vorhandelsmarkt:
3.01
-0.03
-0.99%
Schlusskurs vom Vortag:
$3.00
Offen:
$3.02
24-Stunden-Volumen:
1.26M
Relative Volume:
0.78
Marktkapitalisierung:
$297.63M
Einnahmen:
$40.52M
Nettoeinkommen (Verlust:
$-160.06M
KGV:
-1.6141
EPS:
-1.8834
Netto-Cashflow:
$-165.85M
1W Leistung:
-0.65%
1M Leistung:
+13.86%
6M Leistung:
+9.35%
1J Leistung:
+97.40%
1-Tages-Spanne:
$2.92
$3.16
1-Wochen-Bereich:
$2.77
$3.16
52-Wochen-Spanne:
$1.29
$4.5372
Editas Medicine Inc Stock (EDIT) Company Profile
Firmenname
Editas Medicine Inc
Sektor
Branche
Telefon
617-401-9000
Adresse
11 HURLEY ST., CAMBRIDGE, MA
Compare EDIT vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
EDIT
Editas Medicine Inc
|
3.04 | 297.63M | 40.52M | -160.06M | -165.85M | -1.8834 |
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
794.70 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
Editas Medicine Inc Stock (EDIT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-04-28 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-12-16 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2024-12-13 | Herabstufung | Chardan Capital Markets | Buy → Neutral |
| 2024-12-13 | Herabstufung | Stifel | Buy → Hold |
| 2024-12-13 | Herabstufung | Truist | Buy → Hold |
| 2024-12-11 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2024-11-25 | Herabstufung | BofA Securities | Buy → Underperform |
| 2024-11-06 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2024-11-04 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2024-08-08 | Hochstufung | BofA Securities | Neutral → Buy |
| 2024-05-09 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
| 2023-10-24 | Hochstufung | Citigroup | Neutral → Buy |
| 2023-10-18 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2023-10-17 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2023-09-29 | Hochstufung | Stifel | Hold → Buy |
| 2023-06-12 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2023-02-01 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2022-12-13 | Eingeleitet | Citigroup | Neutral |
| 2022-12-06 | Fortgesetzt | Credit Suisse | Neutral |
| 2022-11-18 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2022-11-18 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2022-09-29 | Eingeleitet | BofA Securities | Neutral |
| 2021-10-19 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2021-09-24 | Eingeleitet | Stifel | Hold |
| 2021-09-10 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2021-08-09 | Hochstufung | Truist | Hold → Buy |
| 2021-08-05 | Hochstufung | Evercore ISI | Underperform → Outperform |
| 2021-06-04 | Fortgesetzt | Robert W. Baird | Outperform |
| 2021-05-04 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2021-04-16 | Eingeleitet | Goldman | Sell |
| 2021-03-22 | Eingeleitet | Credit Suisse | Outperform |
| 2021-03-01 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2021-02-26 | Herabstufung | Truist | Buy → Hold |
| 2021-01-19 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2021-01-07 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2020-12-10 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2020-11-03 | Eingeleitet | Robert W. Baird | Underperform |
| 2020-06-18 | Fortgesetzt | SunTrust | Buy |
| 2020-02-21 | Eingeleitet | Wells Fargo | Equal Weight |
| 2019-04-12 | Eingeleitet | Evercore ISI | Outperform |
| 2018-10-10 | Eingeleitet | Guggenheim | Neutral |
| 2018-09-21 | Eingeleitet | Raymond James | Outperform |
| 2018-05-15 | Bestätigt | Chardan Capital Markets | Buy |
| 2018-02-13 | Eingeleitet | CLSA | Underperform |
| 2018-01-23 | Hochstufung | SunTrust | Hold → Buy |
| 2017-07-14 | Eingeleitet | SunTrust | Hold |
| 2017-03-28 | Eingeleitet | Chardan Capital Markets | Buy |
| 2016-08-10 | Hochstufung | Jefferies | Hold → Buy |
| 2016-06-02 | Eingeleitet | Jefferies | Hold |
| 2016-02-29 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2016-02-29 | Eingeleitet | JP Morgan | Neutral |
| 2016-02-29 | Eingeleitet | Morgan Stanley | Equal-Weight |
Alle ansehen
Editas Medicine Inc Aktie (EDIT) Neueste Nachrichten
Chardan Capital Boosts Editas Medicine (NASDAQ:EDIT) Price Target to $4.00 - MarketBeat
Editas Medicine (NASDAQ: EDIT) cuts Q1 2026 loss as spending falls - Stock Titan
Editas Medicine (NASDAQ:EDIT) Announces Earnings Results - MarketBeat
Editas Medicine Releases Q1 2026 Financial Results - AlphaStreet
Editas Medicine (EDIT) Reports Q1 Loss, Misses Revenue Estimates - Yahoo Finance
Editas Medicine (Nasdaq: EDIT) trims Q1 2026 net loss to $25M - Stock Titan
Editas: Q1 Earnings Snapshot - Barchart.com
Editas targets human testing this year for a one-shot cholesterol gene edit - Stock Titan
Editas Medicine Announces First Quarter 2026 Results and Business Updates - Yahoo Finance
Editas Medicine (EDIT) to Release Quarterly Earnings on Monday - MarketBeat
Editas Medicine SVP Parison sells $957 in stock - Investing.com
Editas Medicine (NASDAQ:EDIT) Rating Increased to Hold at Wall Street Zen - MarketBeat
Editas Medicine (NASDAQ:EDIT) Stock Passes Above Fifty Day Moving AverageHere's Why - MarketBeat
Editas Medicine shares edge higher after Q4 earnings and revenue top estimates - MSN
EDITAS Medicine (NASDAQ: EDIT) advances EDIT-401; IND target mid-2026 - Stock Titan
Editas Medicine (NASDAQ: EDIT) details 2026 virtual meeting, pay vote and in vivo strategy - Stock Titan
Editas Q1 Loss Narrower Than Expected, Revenues Increase Y/Y - MSN
Editas Medicine to present preclinical data on EDIT-401 therapy By Investing.com - Investing.com India
Editas Medicine to present preclinical data on EDIT-401 therapy - Investing.com UK
Upcoming Editas Medicine presentations focus on gene editing research advances - Traders Union
Editas Medicine to Present New Preclinical Data Demonstrating Progress of EDIT-401 as Potential Treatment for Hyperlipidemia at Upcoming Scientific Conferences - ChartMill
Attachment - GlobeNewswire
Gene Editing Tools Market is expected to Hit US$ 1,700.05 Million - openPR.com
Editas Medicine (NASDAQ:EDIT) Share Price Passes Above 50 Day Moving AverageHere's What Happened - MarketBeat
EDIT Financials: Income Statement, Balance Sheet & Cash Flow | Editas Medicine Inc - Stock Titan
Is Editas Medicine going to $0? - MSN
Editas Medicine : Corporate Effectiveness Report April 2026 (b08b29) - marketscreener.com
Neutrolis Appoints Caren Deardorf as Chief Business & Strategy Officer - GlobeNewswire Inc.
Evercore Maintains Editas Medicine(EDIT.US) With Buy Rating, Raises Target Price to $15 - 富途牛牛
Editas Medicine, Inc. (NASDAQ:EDIT) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Editas (EDIT) up 3.8% since last earnings report: Can it continue? - MSN
Editas Medicine (NASDAQ:EDIT) Downgraded by Wall Street Zen to Sell - MarketBeat
Editas (EDIT) Up 3.8% Since Last Earnings Report: Can It Continue? - Yahoo Finance
Editas Medicine, Inc. Files Form 8-K Announcing Changes in Certifying Accountant – April 2026 - Minichart
Editas Medicine appoints PwC as new auditor, dismisses Ernst & Young - Investing.com India
Editas Medicine appoints PwC as new auditor, dismisses Ernst & Young By Investing.com - Investing.com South Africa
Audit shakeup at Editas Medicine (NASDAQ: EDIT) as PwC replaces Ernst & Young - Stock Titan
Growth Value: How correlated is Editas Medicine Inc to the S P500Sell Signal & Safe Capital Investment Plans - baoquankhu1.vn
Can Editas Medicine (EDIT) Stock Beat the Market | Price at $2.73, Up 2.25%Institutional Grade Picks - Cổng thông tin điện tử tỉnh Lào Cai
Price Action: Will Editas Medicine Inc benefit from sector rotation2026 Trade Ideas & Weekly High Conviction Ideas - baoquankhu1.vn
EDIT Should I Buy - Intellectia AI
Gene Editing Market Set to Boom Rapidly by 2033 |CRISPR - openPR.com
EDIT Stock Up on Narrower-Than-Expected Q4 Loss, Revenues Rise Y/Y - Eastern Progress
Volume Report: Can Editas Medicine Inc ride the EV waveGold Moves & Low Risk Entry Point Guides - baoquankhu1.vn
Editas Medicine Inc Stock: Genome Editing Pioneer Faces Key Milestones in Competitive Biotech Landsc - AD HOC NEWS
Fundamentals Check: Will Editas Medicine Inc benefit from sector rotationGap Up & Risk Managed Investment Signals - baoquankhu1.vn
Setup Watch: Does Editas Medicine Inc have strong fundamentals2026 Top Gainers & Expert-Curated Trade Recommendations - baoquankhu1.vn
Editas Medicine Inc. (EDIT) Confirms EDT-401 as Lead Vivo Program - MSN
EDIT PE Ratio & Valuation, Is EDIT Overvalued - Intellectia AI
Editas Medicine Inc Stock: Gene Editing Pioneer Faces Clinical and Market Hurdles in Biotechnology L - AD HOC NEWS
Finanzdaten der Editas Medicine Inc-Aktie (EDIT)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.14%
0.48%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):